Treatment of FXR agonists has been shown to stimulate the expression of hepatic phosphoenolpyruvate carboxylase (PEPCK), a rate-limiting enzyme of gluconeogenesis in various experimental models, including rat hepatoma cells, primary rat or human hepatocytes, and mice [165]. Here, NR1H4 is linked to hepatocellular carcinoma.